This is the Wednesday update. You may submit your own articles / posts by clicking the ‘Submit’ tab on the menu. To comment, click the headline above, and a comment box will appear. Please share this website with your patriot friends and family.
1.) Cam Patterson mandates jabs at UAMS in defiance of state law:
You can help to #fireCam, the over $1 Million a year head of UAMS who runs the place as a wing of the democrat party:
2.) Conway Regional employees sue over vaccine mandate
https://conduitnews.com/2021/11/08/sandiver-lawsuit-conway-regional/
3.) Ontario reports more than 500 confirmed cases of post-vaccine myocarditis or pericarditis
Very significant numbers here. Note the increase in just one week after this report was compiled. Concise, important info here.
4.) new book: The Real Anthony Fauci
https://childrenshealthdefense.salsalabs.org/fauci-book-released-today
5.) Dropping like flies:
https://odysee.com/@JohnThor:0/flies:0
6.) 2019 BioNTech annual report
From the 2019 BioNTech annual report (link below):
“No mRNA immunotherapy has been approved, and none may ever be approved. mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of therapeutics.As a potential new category of therapeutics, to our knowledge, no mRNA immunotherapies have been approved to date by the FDA, EMA or other regulatory agency. Successful discovery and development of mRNA-based (and other) immunotherapies by either us or our collaborators is highly uncertain and depends on numerous factors, many of which are beyond our or their control. To date, there has never been a Phase 3 trial for an mRNA-based product or a commercialized mRNA-based product.”
“Currently, mRNA is considered a gene therapy product by the FDA… Our product candidates may not work as intended, may cause undesirable side effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.As with most biological products, use of our product candidates could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent.
***** “The potential for adverse events is especially acute in the oncology setting, where patients may have advanced disease, have compromised immune and other systems and be receiving numerous other therapies. Undesirable side effects or unacceptable toxicities caused by our product candidates…”***** (emphasis mine – have they not been most stridently recommending s h o t s for immunocompromised, e.g. cancer patients?)
This is unbelievable — lots of concerning elements in this document. I’m stunned. BUT THEY GAVE IT THE GO AHEAD ANYWAY.
https://www.sec.gov/Archives/edgar/data/0001776985/000156459020014536/bntx-20f_20191231.htm#ITEM_3_D